NCT07905677Not yet recruitingPhase 1
Phase 1 Study of VT-101 in Advanced Ovarian Cancer
A Phase 1 Dose-Finding, Safety, and Preliminary Clinical Activity Study of VT-101 in Advanced Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 29 Oct 2026
Brief summary (registry, in English)
This Phase 1, open-label study will evaluate VT-101, an investigational small-molecule therapy, in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer. The primary objectives are to assess the safety, tolerability, and pharmacokinetic profile of VT-101 and to identify a recommended dose for further study. Secondary and exploratory objectives include evaluation of preliminary antitumor activity and characterization of treatment-related effects in participants with limited standard treatment options.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (estimated)
- First submitted
- 23 Oct 2026
- Start date
- 23 Oct 2026
- Primary completion date
- 23 Oct 2029
- Lead sponsor
- Michael J. Goodheart
- Diseases
- Ovarian cancer
- NCT number
- NCT07905677
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 22
- From 23 Oct 2026 to the primary completion date, 23 Oct 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Participants must have advanced, recurrent, or relapsed epithelial ovarian cancer
Lab values
- Medical conditions or laboratory abnormalities that would make study participation unsafe
Age
- Female only
- Age:
- No upper age limit specified
- Healthy Volunteers:
Other
- Does not meet the inclusion criteria
- Other protocol-defined exclusions as determined by the investigator
- Sex:
- 18 years and older
- No
- Healthy volunteers are not eligible
Who the study is looking for
- Female participant
- Age ≥ 18 years
- Histologically confirmed advanced, recurrent, or relapsed epithelial ovarian cancer
- Has received prior standard therapy for ovarian cancer, OR has refused standard therapy, OR is intolerant to standard therapy, OR is not eligible for standard therapy
- ECOG Performance Status of 0, 1, or 2
- Adequate bone marrow, liver, and kidney function as defined by the protocol
- Able to comply with study procedures and provide informed consent
- For women of childbearing potential: agrees to use protocol-required contraception and meets pregnancy testing requirements
Criteria the registry did not label
- ELIGIBILITY CRITERIA
Age in the registry: 18 years to 99 years · Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.